Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
6 papers
Recent·Most cited
B. Gurun, J. W. Tyner, E. Demir…·P. T. Spellman
This paper uses supervised and unsupervised models to identify new methylation pathways and improve AML risk-stratification by analyzing epigenetic changes in progenitor cells.
W. M. Yashar, B. M. Smith, D. J. Coleman…·T. P. Braun
This study shows that combining FLT3 and LSD1 inhibitors synergistically kills FLT3-mutant AML cells by disrupting the MYC super-enhancer complex.
S. A. Carratt, G. L. Kong, B. M. Smith…·J. E. Maxson
This study shows that mutant SETBP1 promotes aggressive myeloproliferative neoplasms by upregulating Myc and its target genes, which can be reversed by epigenetic drugs.
B. M. Smith, J. VanCampen, G. L. Kong…·T. P. Braun
This paper shows that combining KIT and LSD1 inhibitors synergistically kills KIT-mutant AML cells by reducing MYC expression and inactivating PI3K/AKT signaling, supporting a clinical trial.
T. P. Braun, J. Estabrook, L. Darmusey…·J. E. Maxson
This study identifies ASXL1's role in neutrophil differentiation by modulating MYC and RNA Polymerase II, showing its impact on granulocyte maturation and myeloid malignancies.
T. P. Braun, M. Okhovat, C. Coblentz…·J. E. Maxson
The paper identifies mutation synergy between CSF3R and CEBPA in AML, showing their interaction at myeloid lineage enhancers and the requirement of CEBPA mutations as an initial event.